
COCH Stock Forecast & Price Target
COCH Analyst Ratings
Bulls say
Envoy Medical is a hearing health company with a fully implanted active middle ear implant (FI-AMEI) and an investigational cochlear implant in its product portfolio. Their revenue comes primarily from the sale of FI-AMEI implants. The company has successfully completed enrollment for their pivotal trial for their cochlear implant and expects to have all patients complete their 12-month visits by April 2027, with a potential approval window of year-end 2027 to mid-2028. With a positive 10-person team dedicated to key market targets and a potential increase in market adoption due to the fully implanted option, Envoy has significant potential for success in the hearing health market.
Bears say
Envoy Medical is facing several challenges with their leading product, the Esteem FI-AMEI implant, as well as their investigational cochlear implant, Acclaim CI. With limited differentiation between cochlear implants and a complex pathway to adoption, there are concerns about underutilization and potential delays in regulatory approval for the Acclaim CI. Additionally, the company's financials show a history of significant operating losses and reliance on a single-source supplier, making it vulnerable to potential supply chain disruptions. The company's limited cash position and ongoing legal dispute regarding share redemption create further concerns about its financial stability.
This aggregate rating is based on analysts' research of Envoy Medical Inc and is not a guaranteed prediction by Public.com or investment advice.
COCH Analyst Forecast & Price Prediction
Start investing in COCH
Order type
Buy in
Order amount
Est. shares
0 shares